Drugs / curcuma longa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01489592 | Oct 2011 | — | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT05816707 Comparator | May 2024 → Feb 2026 | — | Rania Farouk Mohamed Abdulmaguid | Completed | No outcome recorded |
| Phase 3 | NCT02008981 Comparator | Dec 2013 → Apr 2014 | platelet disorder, undefined | Singapore General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02442453 Comparator | Jan → Nov 2014 | chronic periodontitis | Tatyasaheb Kore Dental College | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Curcuma Longa | “curenext gel containing curcuma longa i.e. turmeric has strong antioxidant and antiinflammatory properties.” NCT02442453 ↗ |
| Route | Oral | “Subjects received a single oral dose of 6 g curcuma containing 2% of curcumin or placebo.” PMID 28370178 ↗ May 2017 |